{
    "nct_id": "NCT06402838",
    "title": "A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers Following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "last_update_time": "2025-09-05",
    "description_brief": "This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain. People who take part in this clinical trial (participants) will be given RO7269162 OR placebo for up to about 1 and a half years. The clinical trial team will see them every 3 weeks in the first 3 months and then every 6 weeks until the end of the trial. These hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The total time of participation in the clinical trial will be 90 weeks.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "RO7269162"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The intervention is RO7269162 given daily by mouth and the study explicitly aims to measure effects on brain amyloid and related biomarkers (amyloid PET, CSF/plasma A\u03b2), indicating a disease-modifying intent directed at Alzheimer pathology rather than a symptomatic cognitive/single-domain enhancer. \ue200cite\ue202turn0search8\ue202turn0search7\ue201",
        "Act: Key extracted details \u2014 drug: RO7269162 (experimental), route: daily oral administration, comparator: placebo, population: amyloid-positive at-risk or prodromal/MCI participants, primary biomarker outcomes include change in brain amyloid load by PET and CSF/plasma A\u03b2 species. The sponsor descriptions state RO7269162 works by altering/slowing production of beta\u2011amyloid peptides (i.e., reducing amyloid generation). \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search7\ue201",
        "Reflect: Classification check \u2014 because RO7269162 is an orally administered small-molecule compound that targets the production/pathology of beta\u2011amyloid (disease biology) and the trial measures amyloid biomarker changes, it fits the definition of a \"disease-targeted small molecule.\" It is not a biologic (monoclonal antibody or vaccine), not described as a symptomatic cognitive enhancer, nor an intervention for neuropsychiatric symptoms. No substantial ambiguity found in the trial documents. \ue200cite\ue202turn0search2\ue202turn0search8\ue201",
        "Web search sources used: Roche trial page (patient info) \u2014 RO7269162 description and study overview. \ue200cite\ue202turn0search0\ue201; Health Research Authority summary \u2014 mechanism note (slows/changes amyloid production) and study details. \ue200cite\ue202turn0search2\ue201; ClinicalTrials summary / trial listing \u2014 title, \"daily oral administration\", and primary biomarker endpoints. \ue200cite\ue202turn0search8\ue201; MedPath / trial registries \u2014 outcome measures listing CSF/plasma A\u03b2 and amyloid PET. \ue200cite\ue202turn0search7\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The trial drug RO7269162 is an oral, disease\u2011targeted small molecule tested to change/slow the production of beta\u2011amyloid and the study explicitly measures amyloid biomarkers (amyloid PET and CSF/plasma A\u03b2), so the intervention is directed at amyloid biology rather than a purely symptomatic/other pathway. \ue200cite\ue202turn3search0\ue202turn3search1\ue201",
        "Act: Key extracted details \u2014 drug: RO7269162 (experimental, oral daily), comparator: placebo; population: amyloid\u2011positive at\u2011risk or prodromal/MCI participants; primary biomarker outcomes include change in brain amyloid by PET and CSF/plasma A\u03b2 species. Roche and regulatory summary pages state RO7269162 acts by preventing or slowing production of toxic beta\u2011amyloid species (i.e., reducing amyloid generation). Based on these explicit statements, assign to CADRO category A) Amyloid beta. \ue200cite\ue202turn0search1\ue202turn3search0\ue201",
        "Reflect: The classification aligns with the trial description and sponsor mechanism \u2014 an orally administered small molecule intended to alter A\u03b2 production fits CADRO A (Amyloid beta). There is no indication the compound primarily targets tau, inflammation, synaptic function, ApoE/lipids, or multiple unrelated pathways in the provided documents, so 'A) Amyloid beta' is the most specific match. If further mechanistic detail (e.g., whether it is a \u03b3\u2011secretase modulator vs BACE inhibitor) is needed, that can be looked up, but the sponsor summaries already state the drug reduces/slows A\u03b2 production. \ue200cite\ue202turn0search6\ue202turn3search1\ue201",
        "Web search results used (key sources cited above): Roche patient/trial page (RO7269162 trial overview). \ue200cite\ue202turn3search1\ue201; Health Research Authority summary (mechanism: slows/changes amyloid production). \ue200cite\ue202turn3search0\ue201; ClinicalTrials trial listing (NCT06402838) \u2014 trial design, oral dosing, biomarker endpoints. \ue200cite\ue202turn0search1\ue201; FDAAA/TrialTracker summary (trial status and dates). \ue200cite\ue202turn0search2\ue201; AdisInsight/phase I profile (pharmacodynamics and prior PD studies). \ue200cite\ue202turn0search6\ue201"
    ]
}